Glycobiology, 2002, Vol. 12, No. 9 563-571
© 2002 Oxford University Press
Constitutively unmasked CD22 on B cells of ST6Gal I knockout mice: novel sialoside probe for murine CD22
2 Department of Molecular Biology, The Scripps Research Institute, 10550 N. Torrey Pines Rd., MEM-L71, La Jolla, CA 92075, USA; 3 Shemyakin Institute of Bioorganic Chemistry, ul Miklukho-Maklaya 16/10, 117997 GSP-7, V-437 Moscow, Russian Federation; 4 Institute of Virology and Immunobiology, University of Würzburg, Versbacherstr. 7, 97078 Würzburg, Germany; and 5 HHMI Department of Cellular and Molecular Medicine, University of California San Diego, CMM-W Bldg., Room 333, 9500 Gilman Dr., 0625, La Jolla, CA 92073, USA
The interaction of CD22 with glycoprotein ligands bearing the Sia
2,6Gal-R sequence is believed to modulate its function as a regulator of B cell signaling. Although a commercial sialoside-polyacrylamide (PAA) probe, NeuAc- 2,6Gal-PAA, has facilitated studies on ligand binding by human CD22, murine CD22 binds instead with high affinity to NeuGc2,6Gal-R. A multivalent probe with this sequence was constructed to facilitate investigations of ligand binding in CD22 function using genetically defined murine models. The probe is based on the sialoside-PAA platform, which is then biotinylated for easy detection. A series of sialoside probes were constructed with two different length linker arms between the sialoside and the backbone and three different sialoside to PAA molar ratios. The NeuGc2,6Gal-PAA probe is specific for CD22: it binds to sialidase-treated B cells of wild-type mice but not B cells of CD22-null mice. Additionally, because the probe only binds to sialidase-treated wild-type cells, it confirms that CD22 is constitutively "masked" on most B cells from wild-type mice by binding to ligands in cis. In contrast, the probe bound equally well to native or sialidase-treated B cells from the immunocompromised ligand-deficient ST6Gal I knockout mice, demonstrating that CD22 is constitutively "unmasked" in these cells.
1 To whom correspondence should be addressed; E-mail: jpaulson{at}scripps.edu
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. E. Collins, O. Blixt, S. Han, B. Duong, H. Li, J. K. Nathan, N. Bovin, and J. C. Paulson High-Affinity Ligand Probes of CD22 Overcome the Threshold Set by cis Ligands to Allow for Binding, Endocytosis, and Killing of B Cells. J. Immunol., September 1, 2006; 177(5): 2994 - 3003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. Grewal, M. Boton, K. Ramirez, B. E. Collins, A. Saito, R. S. Green, K. Ohtsubo, D. Chui, and J. D. Marth ST6Gal-I Restrains CD22-Dependent Antigen Receptor Endocytosis and Shp-1 Recruitment in Normal and Pathogenic Immune Signaling. Mol. Cell. Biol., July 1, 2006; 26(13): 4970 - 4981. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ghosh, C. Bandulet, and L. Nitschke Regulation of B cell development and B cell signalling by CD22 and its ligands {alpha}2,6-linked sialic acids Int. Immunol., April 1, 2006; 18(4): 603 - 611. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Varki and T. Angata Siglecs--the major subfamily of I-type lectins Glycobiology, January 1, 2006; 16(1): 1R - 27R. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nitschke, F. Lajaunias, T. Moll, L. Ho, E. Martinez-Soria, S. Kikuchi, M.-L. Santiago-Raber, C. Dix, R. M. E. Parkhouse, and S. Izui Expression of aberrant forms of CD22 on B lymphocytes in Cd22a lupus-prone mice affects ligand binding Int. Immunol., January 1, 2006; 18(1): 59 - 68. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Tateno, P. R. Crocker, and J. C. Paulson Mouse Siglec-F and human Siglec-8 are functionally convergent paralogs that are selectively expressed on eosinophils and recognize 6'-sulfo-sialyl Lewis X as a preferred glycan ligand Glycobiology, November 1, 2005; 15(11): 1125 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. H. Marino, M. Hoffman, M. Meyer, and K. S. Miller Sialyltransferase mRNA abundances in B cells are strictly controlled, correlated with cognate lectin binding, and differentially responsive to immune signaling in vitro Glycobiology, December 1, 2004; 14(12): 1265 - 1274. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Zhang and A. Varki Cell surface sialic acids do not affect primary CD22 interactions with CD45 and surface IgM nor the rate of constitutive CD22 endocytosis Glycobiology, November 1, 2004; 14(11): 939 - 949. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Collins, O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact PNAS, April 20, 2004; 101(16): 6104 - 6109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Sonnenburg, T. K. Altheide, and A. Varki A uniquely human consequence of domain-specific functional adaptation in a sialic acid-binding receptor Glycobiology, April 1, 2004; 14(4): 339 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Todeschini, W. B. Dias, M. F. Girard, J.-M. Wieruszeski, L. Mendonca-Previato, and J. O. Previato Enzymatically Inactive trans-Sialidase from Trypanosoma cruzi Binds Sialyl and {beta}-Galactopyranosyl Residues in a Sequential Ordered Mechanism J. Biol. Chem., February 13, 2004; 279(7): 5323 - 5328. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-P. Danzer, B. E. Collins, O. Blixt, J. C. Paulson, and L. Nitschke Transitional and marginal zone B cells have a high proportion of unmasked CD22: implications for BCR signaling Int. Immunol., October 1, 2003; 15(10): 1137 - 1147. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Blixt, B. E. Collins, I. M. van den Nieuwenhof, P. R. Crocker, and J. C. Paulson Sialoside Specificity of the Siglec Family Assessed Using Novel Multivalent Probes: IDENTIFICATION OF POTENT INHIBITORS OF MYELIN-ASSOCIATED GLYCOPROTEIN J. Biol. Chem., August 15, 2003; 278(33): 31007 - 31019. [Abstract] [Full Text] [PDF]
|
|